Coated Mongolian Aneurysm Treatment Study 1

Last updated: April 19, 2022
Sponsor: Phenox GmbH
Overall Status: Active - Recruiting

Phase

N/A

Condition

Aneurysm

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT04305626
STUD-192206
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least one unruptured sidewall aneurysm in the anterior circulation
  • No implant (e.g., stent) in the target vessel segment
  • Age >18 years and <80 years
  • Not pregnant and in women of childbearing age, on oral contraception for two yearsfollowing the procedure
  • No participation in another trial
  • No concomitant disease limiting the life expectancy to <2 years
  • No allergy to non-ionic contrast medium or to ASA and P2Y12 receptor antagonists
  • No other neurovascular disorder in the same vascular territory requiring treatment inthe foreseeable future
  • Ability and willingness to comply with the medication requirements within the study,
  • Ability to understand the goal and risks of this study.

Exclusion

Exclusion Criteria:

  • Intracranial aneurysm considered not suitable for FD using p64 MW HPC or p48 MW HPC.
  • Aneurysm previously treated with a device in the parent vessel (e.g., stent, flowdiverter).
  • Another intracranial procedure scheduled for the following 6 months.
  • Age < 18 years and > 80 years.
  • Pregnancy possible or confirmed. Patient not able or willing to arrange contraceptionfor 12 months after treatment.
  • Patient not able or willing to adhere to the study protocol.
  • Patient not able or willing to undergo the scheduled follow-up examinations.

Study Design

Total Participants: 90
Study Start date:
June 22, 2019
Estimated Completion Date:
December 30, 2023

Study Description

Title: Observational Registry With p64 MW HPC and p48 MW HPC in Unruptured Anterior Circulation Aneurysms Under Dual Antiplatelet Medication.

Purpose: To assess safety and effectiveness of p64 MW HPC or p48 MW HPC under Dual Antiplatelet Medication in consecutive patients with unruptured anterior circulation aneurysms.

Follow-up intervals: Independent follow-ups (after 3 to 6 months and after 12 months and after 24 months) according to site specific standard.

Connect with a study center

  • Shastin Central Hospital

    Ulaanbaatar, Bayangol District 10th khoroolol-2
    Mongolia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.